צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Harpoon Therapeutics (HARP)

A strategic alliance with industry leaders strengthens the position of Harpoon Therapeutics (HARP) in solid tumor therapy. The rolling year-over-year relative revenue change confirms the resilience of the model, where the 15.90 level serves as a critical benchmark. Margin stability is ensured by precision cold-chain logistics for components, while integration into a major pharmaceutical behemoth accelerates the development of trispecific antibodies, mitigating pricing risks during the research stage.
Harpoon Therapeutics, Inc. (HARP) - פילוחי מדדים ודוחות פיננסיים

This indicator calculates trailing twelve-month (TTM) revenue dynamics, neutralizing short-term fluctuations to assess the fundamental stability of the business amid a market downturn. By analyzing the TTM sales volume change, an investor determines the margin of safety for Harpoon Therapeutics (HARP), which is supported by the international status of its oncology research and a strategic partnership with a US pharma behemoth.